fam212aa Antibody

What is FAM212A and why is it significant in research?

FAM212A (Family with sequence similarity 212 member A), also known as INKA1 (Inka box actin regulator 1), is a protein that plays multiple critical roles in cellular functions. It was initially identified as INCA (induced in neural crest by AP-2alpha) in Xenopus, where it's primarily expressed in neural crest cells and their derivatives . In mammals, FAM212A has been implicated in neural tube closure, with FAM212A-null mice exhibiting exencephaly . Most significantly, FAM212A has been identified as a major determinant for error-prone processing of deoxyuracils in B cells, antagonizing UNG2 (uracil DNA glycosylase 2) and promoting mutagenic repair during antibody diversification . Additionally, FAM212A functions as an inhibitor of PAK4 (serine/threonine-protein kinase), influencing cytoskeletal dynamics by binding PAK4 in a substrate-like manner .

What are the optimal primary applications for FAM212A antibodies?

FAM212A antibodies are primarily validated for three main applications:

• Western blot (WB): Typically used at dilutions of 1:500-1:2000

• Immunohistochemistry (IHC-P): Recommended dilutions of 1:100-1:200

• Immunocytochemistry/Immunofluorescence (ICC-IF): FITC-conjugated antibodies can be used at 1:50-250 dilutions

For Western blot applications, EL4 cell lysate serves as an effective positive control . The calculated molecular weight of FAM212A is approximately 32 kDa, though observed migration patterns typically show bands at 33 kDa .

How should I validate the specificity of a FAM212A antibody?

To validate FAM212A antibody specificity:

• Blocking peptide validation: Use recombinant protein fragments such as PrEST Antigen FAM212A (containing the immunogen sequence) in blocking experiments . Pre-incubate your antibody with a 100x molar excess of the protein control fragment for 30 minutes at room temperature before application .

• Knockout validation: Compare staining patterns between wild-type samples and FAM212A-knockout models. Studies have used FAM212A-knockout CH12 cells and primary cells from FAM212A-/- mice to confirm antibody specificity .

• Multiple antibody validation: Use antibodies from different vendors or those raised against different epitopes of FAM212A.

• Western blot analysis: Confirm single band detection at the expected molecular weight (~33 kDa) in appropriate positive control samples like EL4 cell lysate .

Which cellular compartments should I expect FAM212A staining in immunofluorescence applications?

FAM212A demonstrates a dynamic subcellular localization pattern:

• Nucleus: FAM212A is primarily nuclear under basal conditions .

• Cytoplasm: It relocalizes to the cytoplasm following interaction with PAK4 .

When designing immunofluorescence experiments, consider co-staining with nuclear markers (DAPI) and PAK4 to observe potential translocation events. In B cells specifically, FAM212A expression peaks in G1 phase of the cell cycle, coinciding with peak AID (Activation-induced cytidine deaminase) activity . This cell-cycle dependent localization is critical for its function in antagonizing UNG2, allowing U·G mispairs to persist into S phase.

How should I optimize FAM212A antibody protocols for detecting changes in expression during B cell activation?

When studying FAM212A in B cells during activation:

• Timing considerations: Fam72a mRNA levels increase approximately 3-fold in LPS-stimulated primary mouse B cells ex vivo, and approximately 20-fold in germinal center B cells in vivo . Design sampling timepoints accordingly.

• Sample preparation:

  • For primary B cells: Isolate splenic B cells and activate with appropriate stimuli (LPS, CIT for CH12 cells)

  • For germinal center B cells: Isolate cells at peak germinal center response (typically days 7-14 post-immunization)

• Controls:

  • Include both resting and activated B cells

  • If possible, use FAM212A-/- and FAM212A+/+ cells as controls

• Detection method optimization:

  • For Western blot: Use 1-2 μg/ml of antibody with EL4 cell lysate as positive control

  • For IHC/IF: Consider using fluorescently-conjugated antibodies for co-localization studies

How does FAM212A function in antibody diversification processes and how can antibodies help study this mechanism?

FAM212A plays a crucial role in three AID-mediated antibody diversification processes:

Research has shown that FAM212A antagonizes UNG2 through direct protein-protein interaction, resulting in reduced UNG2 protein levels during G1 phase of the cell cycle . Anti-FAM212A antibodies are essential tools for co-immunoprecipitation experiments to study this interaction, and for analyzing UNG2 levels by Western blot.

The mutation spectrum observed in FAM212A-/- B cells is opposite to that observed in UNG2-deficient mice, suggesting hyperactive UNG2 in FAM212A-deficient cells . This finding highlights the importance of precise equilibrium between these proteins for proper antibody diversification.

What approaches can resolve contradictory results when FAM212A antibodies show discrepant staining patterns?

When facing discrepant results with FAM212A antibodies:

• Epitope mapping analysis: Different antibodies may target distinct regions of FAM212A. The protein has a known functional domain that interacts with PAK4, and antibodies targeting this region may show different patterns than those targeting other regions .

• Isoform-specific detection: At least two isoforms of FAM212A are known to exist . Verify whether your antibody recognizes both isoforms or is specific to one.

• Cell-cycle dependent expression: FAM212A levels fluctuate during the cell cycle, with peak expression in G1 phase . Synchronize cells to standardize detection.

• Cell-type specific expression: FAM212A expression varies significantly between cell types. In B cells, expression increases ~3-fold with LPS stimulation and ~20-fold in germinal center B cells .

• Validation with multiple methodologies:

  • Use both genetic approaches (siRNA knockdown, CRISPR knockout)

  • Apply both protein (antibody-based) and transcript (qPCR) detection methods

  • Perform complementation experiments by re-expressing FAM212A in knockout cells

How can FAM212A antibodies be utilized to investigate potential links to cancer pathogenesis?

FAM212A overexpression has been observed in many cancers and could promote mutagenesis . To investigate this connection:

• Expression profiling:

  • Use anti-FAM212A antibodies for immunohistochemistry on cancer tissue microarrays

  • Quantify expression levels via Western blot across cancer cell lines

  • Correlate expression with clinical outcomes and genetic instability markers

• Mechanistic studies:

  • Examine UNG2 levels and activity in FAM212A-overexpressing cancer cells

  • Assess DNA repair pathway choice and mutation frequencies

  • Investigate genomic uracil levels using methodologies similar to those in B cell studies

• Functional investigations:

  • Use FAM212A antibodies to monitor protein interactions with PAK4 and UNG2 in cancer cells

  • Perform pull-down assays to identify cancer-specific interacting partners

  • Evaluate FAM212A subcellular localization in relation to DNA damage sites

Studies have shown that FAM212A antagonizes UNG2, resulting in persistence of DNA lesions that can lead to mutagenesis . This mechanism, critical for antibody diversification in B cells, could potentially contribute to genomic instability in cancer when dysregulated.

What are the common technical issues when using FAM212A antibodies and how can they be resolved?

Common issues and solutions when working with FAM212A antibodies:

For Western blot applications specifically, optimize protein loading to 15 μg per lane and consider using concentration gradient experiments (1-2 μg/ml antibody) to determine optimal signal-to-noise ratio .

How should FAM212A antibodies be stored and handled to maintain optimal activity?

For optimal FAM212A antibody performance:

• Storage conditions:

  • Short-term storage (up to 3 months): 4°C

  • Long-term storage: -20°C, avoiding freeze/thaw cycles

• Buffer composition:

  • Most commercial FAM212A antibodies are stored in PBS with 40% glycerol and 0.02% sodium azide at pH 7.2

  • This formulation helps maintain stability during storage

• Handling guidelines:

  • Aliquot antibodies upon first thaw to minimize freeze/thaw cycles

  • Centrifuge briefly before opening vials

  • Avoid contamination by using sterile techniques

• Working solutions:

  • Dilute antibodies in fresh buffer immediately before use

  • For Western blot applications, prepare solutions in blocking buffer containing 1-5% BSA or non-fat milk

  • For immunofluorescence, dilute in PBS containing 0.25% saponin and 1% BSA

How might FAM212A antibodies contribute to understanding neural crest development and related disorders?

FAM212A (initially identified as INCA - Induced in Neural Crest by AP-2alpha) is expressed primarily in neural crest cells and their derivatives . Studies indicate that FAM212A is critical for neural tube closure, with FAM212A-null mice exhibiting exencephaly . Research applications include:

• Developmental timing studies:

  • Use FAM212A antibodies to map expression patterns during neural crest migration

  • Correlate expression with key developmental milestones

  • Create temporal expression atlases across multiple model organisms

• Lineage tracing applications:

  • Combine FAM212A antibodies with neural crest markers to track cell fate decisions

  • Investigate potential roles in epithelial-to-mesenchymal transition

• Disorder-related research:

  • Examine FAM212A expression in neural tube defect samples

  • Investigate potential links to craniofacial abnormalities

  • Study FAM212A-PAK4 interactions in neurodevelopmental contexts

• Therapeutic exploration:

  • Screen for compounds that modulate FAM212A-PAK4 interactions

  • Evaluate effects on neural crest cell migration and differentiation

What are the future prospects for using computational approaches alongside experimental FAM212A antibody data?

Integration of computational approaches with FAM212A antibody data offers promising research directions:

• In silico epitope prediction and antibody design:

  • Use structural modeling to predict optimal epitopes for antibody generation

  • Apply computational protein design strategies like those described in recent literature to generate FAM212A-specific binders

  • Implement machine learning approaches such as AntBO for designing FAM212A-targeting antibodies with improved specificity

• Systems biology integration:

  • Combine FAM212A antibody-based proteomic data with transcriptomic profiles

  • Model interaction networks involving FAM212A, PAK4, and UNG2

  • Predict functional outcomes of FAM212A modulation in different cellular contexts

• Evolutionary analysis:

  • Compare FAM212A expression patterns across species using antibodies with cross-reactivity

  • Current antibodies show cross-reactivity between human, mouse, and rat FAM212A (sequence identity: ~76%)

  • Investigate functional conservation of FAM212A-UNG2 and FAM212A-PAK4 interactions

• Structure-function relationship studies:

  • Use epitope-specific antibodies to probe structural requirements for FAM212A function

  • Develop computational models of FAM212A-UNG2 and FAM212A-PAK4 interactions validated by antibody-based experiments